Evidence map›Paper›PMID 41288875›Full record

ArticleJournal of gastrointestinal cancer2025

Local Recurrence Rates in Locally Advanced Rectal Cancer Are Higher with KRAS Codon 13 Mutations.

Richard Sassun, Annaclara Sileo, Jyi Cheng Ng, Sara Aboelmaaty, Ibrahim A Gomaa, Giulio Mari, Kellie L Mathis, Eric J Dozois, David W Larson

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of gastrointestinal cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Richard Sassun *Division of Colon and Rectal Surgery, Mayo Clinic, 200 First St. Southwest, Rochester, MN, 55905, USA.
Annaclara Sileo *Division of Colon and Rectal Surgery, Mayo Clinic, 200 First St. Southwest, Rochester, MN, 55905, USA.
Jyi Cheng NgDivision of Colon and Rectal Surgery, Mayo Clinic, 200 First St. Southwest, Rochester, MN, 55905, USA.
Sara AboelmaatyDivision of Colon and Rectal Surgery, Mayo Clinic, 200 First St. Southwest, Rochester, MN, 55905, USA.
Ibrahim A GomaaDivision of Colon and Rectal Surgery, Mayo Clinic, 200 First St. Southwest, Rochester, MN, 55905, USA.
Giulio MariDepartment of Colorectal Surgery, ASST Brianza, Desio, MB, Italy.
Kellie L MathisDivision of Colon and Rectal Surgery, Mayo Clinic, 200 First St. Southwest, Rochester, MN, 55905, USA.
Eric J DozoisDivision of Colon and Rectal Surgery, Mayo Clinic, 200 First St. Southwest, Rochester, MN, 55905, USA.
David W LarsonDivision of Colon and Rectal Surgery, Mayo Clinic, 200 First St. Southwest, Rochester, MN, 55905, USA. Larson.David2@mayo.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeDespite advances in oncology regimens and standardization of technical approaches such as total mesorectal excision (TME), local recurrences (LR) remain a significant concern in rectal cancer. This may be due to the complex interplay of genetic mutations driving the disease progression, leading to recurrence associated morbidity and mortality. The association of KRAS mutations on local recurrences in locally advanced rectal cancer (LARC) patients has been less investigated.

methodsPatients from a single-center retrospective database with LARC (2018-2023) were identified and divided into two cohorts: KRAS mutated and KRAS wild-type. A propensity score was used to match the two groups, adjusting for cT/pT stage, tumour grade, extra-mural vessel invasion, lymphovascular/perineural invasion, surgical margins, TME quality, tumour budding, neoadjuvant/adjuvant radiotherapy. Propensity score matching was assessed with Chi-squared tests. Univariate Cox regression analyses were performed to assess KRAS mutations' influence on LR.

results136 patients were included (68 KRAS mutated; 68 KRAS wild-type). The overall LR rate was 8.1%. Adjusted Cox regression analysis revealed that the mutations in codon 13 of KRAS (G13D/G13C) were a significant risk factor for LR (HR = 7.06, p-value = 0.001), with a 33.3% LR rate in those patients. Conversely, other KRAS mutations did not appear to be risk factors for LR (p-value > 0.05).

conclusionThis study suggests codon 13 KRAS mutations may be associated with LR in LARC. However, given the small number patients and events, these findings should be cautiously interpreted until confirmed by larger studies. Preoperative genetic testing for KRAS mutations is suggested to enhance risk stratification.

Indexed as

Neoplasm Recurrence, LocalProto-Oncogene Proteins p21(ras)Rectal NeoplasmsAgedCodonFemaleHumansMaleMiddle AgedMutationRetrospective StudiesRisk FactorsCodonKRAS protein, humanProto-Oncogene Proteins p21(ras)KRASLocal recurrenceOncologic surgeryRectal cancer

Identifiers

PMID41288875

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.